Treatment failure in osteoporosis

A. Diez-Perez*, J. D. Adachi, D. Agnusdei, J. P. Bilezikian, J. E. Compston, S. R. Cummings, R. Eastell, E. F. Eriksen, J. Gonzalez-Macias, U. A. Liberman, D. A. Wahl, E. Seeman, J. A. Kanis, C. Cooper

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Summary: Guidelines concerning the definition of failure of therapies used to reduce the risk of fracture are provided. Introduction: This study aims to provide guidelines concerning the definition of failure of therapies used to reduce the risk of fracture. Methods: A working group of the Committee of Scientific Advisors of the International Osteoporosis Foundation was convened to define outcome variables that may assist clinicians in decision making. Results: In the face of limited evidence, failure of treatment may be inferred when two or more incident fractures have occurred during treatment, when serial measurements of bone remodelling markers are not suppressed by antiresorptive therapy and where bone mineral density continues to decrease. Conclusion: The provision of pragmatic criteria to define failure to respond to treatment provides an unmet clinical need and may stimulate research into an important issue.

Original languageEnglish
Pages (from-to)2769-2774
Number of pages6
JournalOsteoporosis International
Volume23
Issue number12
DOIs
StatePublished - Dec 2012

Funding

FundersFunder number
International Osteoporosis Foundation
Servier
AMGEN
AMGEN
Procter & Gamble Pharmaceuticals
Novartis
ONO-Pharma
Astex Pharmaceuticals
Pfizer
Osteologix
Nestle Research Center, New Zealand Milk Limited
AMGEN
Lilly Industries
Roche
Novo Nordisk
AstraZeneca
Organon Laboratories
Kyphon Inc.

    Keywords

    • Bone mineral density
    • Fractures
    • Markers of bone turnover
    • Osteoporosis
    • Treatment

    Fingerprint

    Dive into the research topics of 'Treatment failure in osteoporosis'. Together they form a unique fingerprint.

    Cite this